BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.